Free Trial
NYSE:BLCO

Bausch + Lomb 4/30/2025 Earnings Report

Bausch + Lomb logo
$11.47 -0.12 (-1.04%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$11.49 +0.02 (+0.17%)
As of 05/2/2025 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb EPS Results

Actual EPS
-$0.07
Consensus EPS
$0.03
Beat/Miss
Missed by -$0.10
One Year Ago EPS
$0.07

Bausch + Lomb Revenue Results

Actual Revenue
$1.15 billion
Expected Revenue
$1.15 billion
Beat/Miss
Beat by +$367.00 thousand
YoY Revenue Growth
+3.50%

Bausch + Lomb Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Bausch + Lomb Earnings Headlines

Citigroup Cuts Bausch + Lomb (NYSE:BLCO) Price Target to $13.00
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
Bausch + Lomb Posts Wider Loss In Q1
See More Bausch + Lomb Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bausch + Lomb? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bausch + Lomb and other key companies, straight to your email.

About Bausch + Lomb

Bausch + Lomb (NYSE:BLCO) operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

View Bausch + Lomb Profile

More Earnings Resources from MarketBeat